On Friday, the US Food and Drug Administration (FDA) approved as the first interchangeable biosimilar to Swiss pharma giant Roche's (ROG: SIX) anti-IgE monoclonal antibody Xolair (omalizumab). The FDA ...

Omlyclo is the first interchangeable biosimilar to omalizumab (Xolair; Genentech, Novartis). Omlyclo was approved to treat the same conditions as Xolair. The FDA approved Celltrion’s omalizumab ...

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small ...

MONDAY, March 3, 2025 (HealthDay News) — Omalizumab is superior to oral immunotherapy (OIT) for multifood allergy, and most patients include dietary consumption (DC) of allergy-triggering foods after ...

In the ASTERIA I and ASTERIA II trials, omalizumab demonstrated significant efficacy for patients aged 12 to 75 years who remained symptomatic despite optimized H1 antihistamine therapy. Patients ...

Thirty-six percent of patients treated with omalizumab were able to tolerate 2000mg of peanut protein and 2 other food allergens without experiencing an allergic reaction compared with 19% of OIT ...

Stage 2 of the OUtMATCH study showed Xolair was more effective with fewer side effects than multi-allergen oral immunotherapy (OIT) in the first-ever head-to-head trial comparing the two treatment ...

Oral chemotherapy kills or weakens cancer cells. It comes in the form of a pill, liquid, or tablet that a person swallows or places under the tongue to dissolve. It is not suitable for all stages ...

Robert A. Wood, MD, FAAAAI, looks back on the first year of omalizumab’s use for food allergy. Patients often are allergic to multiple foods or to foods that are difficult to avoid. Perspective ...

Xolair (omalizumab) is a brand-name subcutaneous injection that’s prescribed for hives, asthma, and other conditions. This article covers topics such as side effects, dosage, and how Xolair ...

Demographic, clinical, laboratory, and spirometric data for two severe asthma patients receiving treatment with omalizumab for more than 10 years. In the present study, neither patient experienced ...